echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Another Adamu monoanti-biosimilar drug was approved for intensive admission by the drug King Xiumeile competitors.

    Another Adamu monoanti-biosimilar drug was approved for intensive admission by the drug King Xiumeile competitors.

    • Last Update: 2020-07-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Mylan and Concord Kirin jointly announced that the U.SFDA has approved Hulio (adalimumab-fkjp), a biosimilar drug for the use® of a variety of autoimmune diseases, including rheumatoid arthritis, juvenile autoarthritis (4 years and older), psoriasis, aggressive spinal inflammation, adult Crohn's disease, aggressive colitis, and progressive colonitisit is understood that this is the FDA approved the sixth adamuzumatic biosimilar drugin addition to the United States, the monopoly position of the ® in the global market is gradually challenged by many biological analoguespatent expires, Shumel® U.Sand European markets hit Adamum monotonia injection stakes are the world's first approved all-human anti-tumor necrosis ɑ (TNF-ɑ) monoclonal antibodies, first developed by The U.Spharmaceutical giant AbbVie, the product called Humira, first approved by the U.SFDA in 2002currently available in more than 90 countries and countries around the world, The ubisoft ®, approved indications include rheumatoid arthritis, hyperthyroidism, psoriasis, juvenile iearthritis, Crohn's disease, ulcerative colitis, septic adhemitis, and so onbecause of the widespread indications, Semelo ® has created a miracle in drug sales for many yearssince 2012, Adamu monotogens have been at the top of the global prescription drug sales list, known as the "drug king.", in 2018, The u.Sdollars in global sales ® reached $20.5 billion, while sales of the ® in 2019 declined, but the global sales of $19.17 billion remain edited at the top of the global drug sales listsuch a huge cake, naturally there are many competitorsit is understood that the patent of the ® of Sumerano expires in the United States, China and Europe in 2016-2018, and its monopoly in the global market is gradually being challenged by biosimilars, the United States and Europe are the two most important markets in the world ®in the U.S market, AbbVie has reached patent litigation settlements with nine pharmaceutical companies to defend the patent protection of the U.S market for the® U.S market, putting Themele ® patent protection period firmly in 2023 even so, Sumera's U.S sales growth slowed from 10.7 percent in 2018 to 8.6 percent in 2019 According to the latest statistics, the FDA has approved a total of six Adamu monotomades biosimilar drugs in the European market, after the® loss of patent protection in October 2018, a number of biosimilars such as Imraldi (Samsung Bioepis), Amgen , Cylezo (Bollinger Ingerham), Hyrimoz (Sanders), Hulio (Mylan/Concord Fermentation) landed on the market and quickly encroached on The European Market , Imraldi has reportedly accounted for the largest share of the biosimilar stake in the European market, followed by Amgevita Amgevita annual report, The u.S ® sales outside the U.S in 2019 were $4.305 billion, down 31.1 percent from a year earlier noble drugs sold for civilian prices, The Chinese market is still difficult in February 2010, Xiu Meile ® approved in China despite being branded "drug king", The u® in China's market penetration rate is not high, sales have been flat for a decade , in 2018, Sumele ® China sales of less than 400 million yuan, accounting for about 0.2% of global sales, drug penetration rate is lower than the global average industry generally believes that this has something to do with its high prices and less approved indications currently only six of the ® approved in China are rheumatoid arthritis, hyper-directed spina, psoriasis, multi-joint infant inoarthritis (2019.11), moderate to severe active Crohn's disease (2020.1.8), and vitinoiditis (2020.3) in the United States, Europe and other markets under the fierce offensive of biological-similar drugs, AbbVie began to attach importance to China's incremental market, since 2019, the country announced the price of the ®, initially from 7600 yuan per unit to 3,160 yuan, a drop of nearly 60%, the industry agreed that The ® this move is to provide a way to enter health care and then, in 2019, abbreviant's Siomer ® was added to the national health insurance list, with a medic-paying standard of 1,290 yuan per branch and a civilian price sold for the drug at the same time, industry insiders say AbbVie began to expand the Sioher ® related sales force despite this, Xiu Meile ® in the domestic face of competition will be more and more intense, similar products Such as Isep and other drugs have also entered the national health insurance catalog , in 2016, the core patent for the ® of Sumele expired in China many Chinese companies have begun to attack the market monopoly of The melo® , the Adamu monoanti-biosimilars of Baiotai and Haizheng Pharmaceuticals have been officially approved at the end of 2019 , the price of the Greeli ® of Bai Otai is 1160 yuan / branch, Haizheng Pharmaceuticals' An Jianning ® price is 1150 yuan / branch, are slightly lower than the standard of payment for the medical insurance ® 1290 yuan / branch in addition, according to the medical magic cube monitoring, the ® in the recent bidding in Qinghai Province and Zhejiang and Hunan Province has reduced the price to 1150 yuan, the first quarter for Bai Otai contributed 1972.61 million yuan of sales in addition, it is understood that Zhengda Tianqing, Cinda Bio and Fu Hong Hanxuan have submitted their listing applications According to Frost Sullivan, the market size of China's Adamu monotodrine biosimilars will increase to 4.7 billion yuan by 2023 and 11.5 billion yuan by 2030 thus, in the increasingly fierce competition, Adamu monoanti-biosimilarwar is imminent, for the already bowed in China's Xiu Meile ®, the future of the future seems to be not good reference source: 1 Sina Medicine: "Sumeile again to meet the opponent!" Domestic 2nd Adamu single resistance is about to be approved, the price war has begun? 2 Medicine First Time: FDA Approves 6th Adamu Monoanti-Biosimilar Stakes 3.Pharmaceutical Rubik's Cube: "Aotai" Adamu Singa-Resistant Price Reduction First Quarter Sales Of About 19 Million" 4 Pharmaceutical: "The Rise of Adamu Monoanti-Biosimilars"
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.